Stocks

Second consecutive quarter of Cash EBITDA1 growth CALGARY, Alberta, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Quorum Information Technologies Inc. (TSX-V: QIS) (“Quorum”), a North American SaaS Software and Services company providing essential enterprise solutions that automotive dealerships and Original Equipment Manufacturers (“OEMs”) rely on …

With its stock down 16% over the past three months, it is easy to disregard Temple & Webster Group (ASX:TPW). It is possible that the markets have ignored the company's differing financials and decided to lean-in to the negative sentiment. Fundamentals usually dictate market …

With its stock down 38% over the past three months, it is easy to disregard Nine Entertainment Holdings (ASX:NEC). However, the company's fundamentals look pretty decent, and long-term financials are usually aligned with future market price movements. In this article, we decided to focus …

Bapcor stock has recently seen an updated price target, attributed to a modest rise in the discount rate from 7.70% to 8.02%. This shift reflects both optimism about the company’s long-term valuation as well as caution prompted by broader economic dynamics. Stay tuned to …

As the Australian market navigates a period of correction, influenced by global economic factors and local financial dynamics, investors are keenly observing sectors like materials and IT for potential opportunities. Amidst these fluctuations, penny stocks—though an older term—remain a compelling area for exploration due …

The Australian market has been experiencing a correction, influenced by global economic factors and local market dynamics, with sectors like materials showing resilience due to recovering commodity prices. In this environment of fluctuating indices and cautious investor sentiment, identifying promising small-cap stocks can offer …

Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®1, 89Zr-DFO-girentuximab) PET/CT2 would have …